Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
FDA approves Abraxane, first in new class of protein-bound particle drug
February 20th, 2005
American Pharmaceutical Partners, Inc., (APPX) (APP), and American Bioscience, Inc., (ABI) announced that the U.S. Food and Drug Administration (FDA) has approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer. Abraxane is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The approval marks a new class of "protein-bound particle" drugs, now made possible by...
Source: Medical Letter on the CDC & FDA (2005-02-20)
|
